Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Drug Discov Today. 2023 Jun;28(6):103551. doi: 10.1016/j.drudis.2023.103551. Epub 2023 Mar 11.
Drug discovery is arguably a highly challenging and significant interdisciplinary aim. The stunning success of the artificial intelligence-powered AlphaFold, whose latest version is buttressed by an innovative machine-learning approach that integrates physical and biological knowledge about protein structures, raised drug discovery hopes that unsurprisingly, have not come to bear. Even though accurate, the models are rigid, including the drug pockets. AlphaFold's mixed performance poses the question of how its power can be harnessed in drug discovery. Here we discuss possible ways of going forward wielding its strengths, while bearing in mind what AlphaFold can and cannot do. For kinases and receptors, an input enriched in active (ON) state models can better AlphaFold's chance of rational drug design success.
药物发现可以说是一个极具挑战性和重要的跨学科目标。人工智能驱动的 AlphaFold 的惊人成功,其最新版本得益于一种创新的机器学习方法,该方法整合了关于蛋白质结构的物理和生物知识,这无疑提高了药物发现的希望,但这些希望并未实现。尽管模型准确,但它们是僵化的,包括药物口袋。AlphaFold 的混合性能提出了一个问题,即如何利用它的优势进行药物发现。在这里,我们讨论了利用其优势的可能方法,同时牢记 AlphaFold 能做什么和不能做什么。对于激酶和受体,富含活性(ON)状态模型的输入可以提高 AlphaFold 合理药物设计成功的机会。